Concepts (104)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Killer Cells, Natural | 3 | 2021 | 214 | 1.350 |
Why?
|
| Burkitt Lymphoma | 5 | 2023 | 56 | 1.330 |
Why?
|
| Malaria, Falciparum | 3 | 2023 | 115 | 0.990 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2023 | 90 | 0.920 |
Why?
|
| CD56 Antigen | 2 | 2020 | 15 | 0.790 |
Why?
|
| Cytomegalovirus Infections | 3 | 2018 | 69 | 0.750 |
Why?
|
| Cytomegalovirus | 3 | 2018 | 88 | 0.730 |
Why?
|
| Graft Rejection | 3 | 2018 | 257 | 0.700 |
Why?
|
| Receptors, IgG | 1 | 2020 | 36 | 0.690 |
Why?
|
| Plasmodium falciparum | 1 | 2019 | 132 | 0.600 |
Why?
|
| Immune System | 1 | 2019 | 129 | 0.600 |
Why?
|
| B7-H1 Antigen | 1 | 2016 | 53 | 0.520 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 197 | 0.510 |
Why?
|
| Herpesvirus 8, Human | 2 | 2023 | 21 | 0.400 |
Why?
|
| Sarcoma, Kaposi | 2 | 2023 | 17 | 0.380 |
Why?
|
| Herpesvirus 4, Human | 5 | 2023 | 181 | 0.340 |
Why?
|
| Kidney Transplantation | 3 | 2018 | 258 | 0.310 |
Why?
|
| Kenya | 4 | 2023 | 81 | 0.300 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 47 | 0.280 |
Why?
|
| Tissue Donors | 2 | 2018 | 132 | 0.270 |
Why?
|
| Child | 5 | 2023 | 4301 | 0.240 |
Why?
|
| Graft Survival | 2 | 2016 | 279 | 0.210 |
Why?
|
| Humans | 18 | 2024 | 59343 | 0.200 |
Why?
|
| Microbiota | 1 | 2023 | 106 | 0.190 |
Why?
|
| Receptors, KIR | 1 | 2021 | 3 | 0.190 |
Why?
|
| Signaling Lymphocytic Activation Molecule Family | 1 | 2020 | 5 | 0.180 |
Why?
|
| Herpesviridae Infections | 1 | 2020 | 28 | 0.180 |
Why?
|
| Herpesviridae | 1 | 2020 | 14 | 0.180 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 195 | 0.170 |
Why?
|
| Child, Preschool | 3 | 2021 | 1838 | 0.170 |
Why?
|
| Malaria Vaccines | 1 | 2019 | 24 | 0.160 |
Why?
|
| Antimalarials | 1 | 2019 | 68 | 0.160 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 672 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2019 | 265 | 0.150 |
Why?
|
| Genes, MHC Class I | 1 | 2018 | 28 | 0.150 |
Why?
|
| Flow Cytometry | 1 | 2020 | 671 | 0.150 |
Why?
|
| Immunotherapy | 1 | 2020 | 229 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 163 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 238 | 0.140 |
Why?
|
| Antibodies, Viral | 3 | 2024 | 307 | 0.140 |
Why?
|
| Vaccination | 1 | 2019 | 337 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2020 | 735 | 0.140 |
Why?
|
| Transplant Recipients | 1 | 2016 | 31 | 0.130 |
Why?
|
| Cell Differentiation | 2 | 2021 | 1295 | 0.130 |
Why?
|
| Lung Transplantation | 1 | 2016 | 47 | 0.130 |
Why?
|
| Prognosis | 2 | 2019 | 1565 | 0.130 |
Why?
|
| Confidence Intervals | 1 | 2016 | 256 | 0.130 |
Why?
|
| MicroRNAs | 1 | 2019 | 617 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1061 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 646 | 0.110 |
Why?
|
| Infant | 3 | 2023 | 1527 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2021 | 5981 | 0.100 |
Why?
|
| Alleles | 2 | 2023 | 424 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 2466 | 0.090 |
Why?
|
| Animals | 4 | 2023 | 19620 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2010 | 158 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 293 | 0.080 |
Why?
|
| Female | 5 | 2024 | 30847 | 0.070 |
Why?
|
| Middle Aged | 3 | 2024 | 16242 | 0.070 |
Why?
|
| Male | 4 | 2024 | 27505 | 0.070 |
Why?
|
| Adult | 2 | 2024 | 15745 | 0.060 |
Why?
|
| Saliva | 1 | 2024 | 96 | 0.060 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2023 | 5 | 0.060 |
Why?
|
| Feeding Methods | 1 | 2023 | 9 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2023 | 65 | 0.050 |
Why?
|
| Nucleocapsid Proteins | 1 | 2023 | 34 | 0.050 |
Why?
|
| Parturition | 1 | 2023 | 53 | 0.050 |
Why?
|
| Rituximab | 1 | 2023 | 82 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2022 | 34 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2023 | 97 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2022 | 59 | 0.050 |
Why?
|
| Pregnant Women | 1 | 2023 | 92 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2023 | 454 | 0.050 |
Why?
|
| Endemic Diseases | 1 | 2021 | 14 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2022 | 177 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 451 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 278 | 0.040 |
Why?
|
| Viral Load | 1 | 2021 | 228 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 373 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2019 | 47 | 0.040 |
Why?
|
| Adolescent | 2 | 2021 | 5921 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2023 | 1095 | 0.040 |
Why?
|
| Coinfection | 1 | 2020 | 45 | 0.040 |
Why?
|
| Genotype | 1 | 2021 | 642 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 259 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 1371 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 387 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 10260 | 0.040 |
Why?
|
| Massachusetts | 1 | 2024 | 2086 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2022 | 609 | 0.040 |
Why?
|
| Computational Biology | 1 | 2019 | 325 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2018 | 51 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2018 | 131 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 165 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2018 | 216 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2018 | 353 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1518 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2352 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 2064 | 0.030 |
Why?
|
| Virus Activation | 1 | 2010 | 24 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 232 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 13308 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2010 | 314 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 5145 | 0.010 |
Why?
|